Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer (WJOG9216G)
Ontology highlight
ABSTRACT: Interventions: Arm A: FOLFIRI plus ramucirumab (Rmab) treatment
- Rmab: 8 mg/kg/day1
- l-leucovorin (l-LV): 200 mg/m2/day1
- irinotecan (IRI): 180 mg/m2/day1
- bolus 5-FU: 400 mg/m2/day1
- infusional 5-FU: 2400 mg/m2/day1-3
Every 2 weeks
Arm B: FOLFOXIRI plus Rmab treatment
Induction therapy: 8 courses (maximum of 12 courses)
- Rmab: 8 mg/kg/day1
- IRI: 165 mg/m2/day1
- l-LV: 200 mg/m2/day1
- oxaliplatin (OX): 85 mg/m2/day1
- infusional 5-FU: 3200 mg/m2/day1-3
Every 2 weeks
Maintenance therapy: 5-FU/l-LV+Rmab, every 2 weeks
Primary outcome(s): Objective response rate
Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
DISEASE(S): First-line Treatment In Patients With Metastatic Colorectal Cancer
PROVIDER: 2614896 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA